← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 1, 2014Last known activity
Jan 1, 2026
Timeline
1960s
- Jan 1, 1960
Jiangsu Cancer Institute & Hospital— Founded
Drugs by trial phase (55 distinct, 41 trials)
Phase 4 (9 own, 0 via acquisition)
Phase 3 (16 own, 0 via acquisition)
Phase 2 (28 own, 0 via acquisition)
Indications
Studied for
- Adnexal Diseases
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Colorectal Neoplasms
- Endocrine Gland Neoplasms
- Endocrine System Diseases
- Fallopian Tube Neoplasms
- Gastrointestinal Stromal Tumors
- Genital Neoplasms, Female
- Gonadal Disorders
- Head and Neck Neoplasms
- Hypersensitivity
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Nasopharyngeal Carcinoma
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Ovarian Diseases
- Ovarian Neoplasms
- Sarcoma
- Squamous Cell Carcinoma of Head and Neck
- Urogenital Neoplasms
- Uterine Cervical Neoplasms
Recent trials (50)
- NCT07311577Sponsor investigatorPhase 2Jan 1, 2026
- NCT07311577Lead sponsorPhase 2Jan 1, 2026
- NCT07286942Sponsor investigatorPhase 2Dec 18, 2025
- NCT07286942Lead sponsorPhase 2Dec 18, 2025
- NCT07082179Sponsor investigatorPhase 2Aug 31, 2025
- NCT07082179Lead sponsorPhase 2Aug 31, 2025
- NCT07055399CollaboratorPhase 2Aug 21, 2025
- NCT07009925Lead sponsorPhase 2Jun 30, 2025
- NCT07009925Sponsor investigatorPhase 2Jun 30, 2025
- NCT06848439Lead sponsorPhase 2Jun 15, 2025
- NCT06848439Sponsor investigatorPhase 2Jun 15, 2025
- NCT07002346CollaboratorPhase 3Jun 1, 2025
- NCT06985602Lead sponsorPhase 2May 16, 2025
- NCT06985602Sponsor investigatorPhase 2May 16, 2025
- NCT06985602OfficialPhase 2May 16, 2025
Details
- Founded
- Nanjing, CN Jan 1, 1960
- Last known activity
- Jan 1, 2026